Human FGF-19 DTSet enzyme-linked immunoassay kit
| Specification | 96*5 Test；96T*15 Test |
|---|---|
| Standard Curve Range | 15.63pg/ml-1000pg/ml |
| Standard Curve Gradient | 7 Points/3 Folds |
| Number of Incubations | 2 |
| Sample Volume | 50 μl |
| Type | Not Ready-to-Use |
| Test Duration | 120min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0399 | 0.0366 | 0.0383 | |
| 15.63 | 0.1331 | 0.1290 | 0.1311 | 0.0928 |
| 31.25 | 0.2248 | 0.2205 | 0.2227 | 0.1844 |
| 62.50 | 0.4076 | 0.4103 | 0.4090 | 0.3707 |
| 125.00 | 0.7020 | 0.7582 | 0.7301 | 0.6919 |
| 250.00 | 1.3920 | 1.4060 | 1.3990 | 1.3608 |
| 500.00 | 2.3510 | 2.5800 | 2.4655 | 2.4273 |
| 1000.00 | 3.8820 | 4.0277 | 3.9549 | 3.9166 |
Product Features
- Optimized capture and detection antibody pairings with recommended concentrations save lengthy development time
- Development protocols are provided to guide further assay optimization
- Assay can be customized to your specific needs
- Economical alternative to complete kits
Kit Content
- Capture Antibody
- Detection Antibody
- Recombinant Standard
- Streptavidin conjugated to horseradish-peroxidase (Streptavidin-HRP)
Other Reagents Required
DTSet Ancillary Reagent Kit (5 plates): containing 96 well microplates, plate sealers, substrate solution, stop solution, plate coating buffer (PBS), wash buffer, and assay buffer.
- 96 well microplates: YOUKE Life, Catalog # DSEP01. Plate Sealers: YOUKE Life, Catalog # DSSF01.
- Coating Buffer: 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.2-7.4, 0.2 μm fi ltered . YOUKE Life, Catalog # DSCB01.
- Blocking Buffer: YOUKE Life, Catalog # DSBB01.
- Wash Buffer: 0.05% Tween 20 in PBS, pH 7.2-7.4. YOUKE Life, Catalog # DSWB01.
- Assay Buffer: 0.5%BSA，0.05%Tween20，PBS Solution.YOUKE Life, Catalog # DSAB01
- Substrate Solution: Tetramethylbenzidine. YOUKE Life, Catalog # DSTS01.
- Stop Solution: 0.5mol/ml H2SO4. YOUKE Life, Catalog # DSSS01.
Product Data Sheet
Background: FGF-19
The Fibroblast Growth Factor (FGF) family consists of at least 22 highly conserved proteins and are found in many species ranging from C. elegans and Drosophila to humans. FGFs are heparin-binding growth factors with a core 120 amino acid (aa) FGF domain that allows for a common tertiary structure. In general, FGFs are expressed during embryonic development and in restricted adult tissues. They act on cells of mesodermal and neuroectodermal origin to regulate diverse physiologic functions including angiogenesis, cell growth, pattern formation, metabolic regulation, cell migration, neurotrophic effects, and tissue repair. The activities of the FGF family are mediated by four receptors, FGF R1 through FGF R4. The receptors are transmembrane proteins with a tyrosine kinase domain and are thought to act as classical receptor tyrosine kinases. FGF R5/FGF RL1 has also been described, but lacks the kinase domain and signaling capability.
Human FGF-19 cDNA predicts a 251 aa precursor protein with a 22 aa signal peptide and a 229 aa secreted mature protein with no potential N-linked glycosylation sites. It shares approximately 50% aa sequence identity with mouse and rat FGF-15 and 62% aa sequence identity with chicken FGF-19. Unlike most FGFs, which bind to and activate more than one FGF receptor, FGF-19 appears to bind only FGF R4. Receptor binding is capable of activating MAP Kinase and inducing the Prolactin promoter. FGF-19 has two putative disulfide bonds, one of which is conserved in the FGF family. Uniquely, it also has an extended loop structure that may affect heparan sulfate binding.
The functional roles of FGF-19 continue to be elucidated and include developmental, metabolic, and tumorigenic activities. During chick embryogenesis, FGF-19 has been shown to act synergistically with Wnt-8c to initiate inner ear development. However, the mouse FGF-19 ortholog, FGF-15, is not required for this activity. FGF-19 is also expressed in the embryonic chicken eye where it may play a role in lens development. Questions regarding the functions of human FGF-19 have been addressed using ectopic expression. Transgenic over-expression of human FGF-19 in mice results in tumor formation, increased energy expenditure, decreased adiposity, and a resistance to weight gain in response to a high fat diet. Similar affects have been observed in mice treated intravenously with recombinant FGF-19.
